Hangzhou Shangjian Biotechnology Co., Ltd.
PrivateLast Round
Series B
Extension
Dec 30, 2021
Total Funding Raised
$32.34M
Company Overview
Hangzhou Shangjian Biotechnology Co., Ltd. is a biopharmaceutical company focused on the research and development of novel antibody therapeutics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hangzhou Shangjian Biotechnology Co., Ltd. Comparables
Compare Hangzhou Shangjian Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TJ Biopharma | 87% | |
| CASI Pharmaceuticals | 79% | |
| Johnson & Johnson | 73% |
Hangzhou Shangjian Biotechnology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 30, 2021 | ||||
| Series B | Sep 15, 2020 | ||||
| Series A Extension | Jan 1, 2019 | ||||
| Series A | Jun 1, 2018 | ||||
| Angel | Mar 1, 2017 |
Hangzhou Shangjian Biotechnology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Zheshang Venture Capital | Series B Extension |
| Zhejiang Sino Wisdom Investment Management | Series B |
| BOCOM International Holdings Company Limited | Series B |
| Addor Capital | Series B Extension, Series B |
| Hankang Capital | Series B Extension, Series A |
| Cowin Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2020
$32M round led by Addor Capital, Cowin Capital, and Zhejiang Sino Wisdom.
- Jun 1, 2018
Hankang Capital led the Series A round.
Hangzhou Shangjian Biotechnology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hangzhou Shangjian Biotechnology Co., Ltd.'s valuation, stock price, and market status.
Is Hangzhou Shangjian Biotechnology Co., Ltd. a public or private company?
Hangzhou Shangjian Biotechnology Co., Ltd. is a private company.
What is the current stock price of Hangzhou Shangjian Biotechnology Co., Ltd.?
Hangzhou Shangjian Biotechnology Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.
How much is Hangzhou Shangjian Biotechnology Co., Ltd. worth (valuation)?
Valuation information for Hangzhou Shangjian Biotechnology Co., Ltd. is not publicly available.
Can I buy Hangzhou Shangjian Biotechnology Co., Ltd. stock?
Hangzhou Shangjian Biotechnology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Hangzhou Shangjian Biotechnology Co., Ltd.'s last funding round?
Hangzhou Shangjian Biotechnology Co., Ltd.'s most recent funding round was Series B Extension on December 30, 2021.
Who are the main investors in Hangzhou Shangjian Biotechnology Co., Ltd.?
Key investors in Hangzhou Shangjian Biotechnology Co., Ltd. include Zhejiang Sino Wisdom Investment Management, Addor Capital, Hankang Capital, Cowin Capital.
Will Hangzhou Shangjian Biotechnology Co., Ltd. IPO soon?
No public IPO plans have been announced for Hangzhou Shangjian Biotechnology Co., Ltd..
How can I track Hangzhou Shangjian Biotechnology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hangzhou Shangjian Biotechnology Co., Ltd.'s secondary market activity and sign up for updates.